Core Viewpoint - The company reported its 2025 performance, which met expectations with a slight decline in revenue but a modest increase in net profit, indicating stability in its operations and potential for future growth [1][2]. Performance Review - In 2025, the company's revenue was 575.17 billion RMB, a year-on-year decrease of 1.6%, while the net profit attributable to shareholders was 7.155 billion RMB, an increase of 1.5%, resulting in earnings per share of 2.29 RMB, aligning with expectations [1]. - The distribution business showed steady development, with distribution revenue at 435.39 billion RMB, down 2.0% year-on-year, and a segment operating profit margin of 2.73%. The company is enhancing direct sales to high-grade hospitals and retail terminals, with market share growing rapidly in Jiangsu, Zhejiang, Shanghai, and Beijing [1]. Development Trends - Retail revenue reached 38.38 billion RMB in 2025, reflecting a year-on-year growth of 6.7%, with a segment operating profit margin of 1.56%. The professional pharmacy segment benefited from outpatient prescriptions and achieved over 15% revenue growth [2]. - The medical device distribution revenue was 115.54 billion RMB, down 2.0% year-on-year, with a segment operating profit margin of 2.23%. The revenue from medical consumables showed stable growth, while sales of IVD products and medical equipment declined [2]. - The company aims to optimize its business structure to maintain a relatively stable gross margin, with a comprehensive gross margin of 7.25%, down 0.32 percentage points year-on-year [2]. Profit Forecast and Valuation - Due to some business adjustments, the company has lowered its 2026 net profit forecast by 5% to 7.53 billion RMB and introduced a 2027 net profit estimate of 7.92 billion RMB. The current stock price corresponds to 7.5 times and 7.0 times the price-to-earnings ratio for 2026 and 2027, respectively [3]. - The company maintains an outperform rating and a target price of 24.7 HKD, which corresponds to 9.1 times and 8.5 times the price-to-earnings ratio for 2026 and 2027, indicating an upside potential of 22.3% [3].